These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1084 related articles for article (PubMed ID: 15982396)
1. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
2. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Prati R; Apple SK; He J; Gornbein JA; Chang HR Breast J; 2005; 11(6):433-9. PubMed ID: 16297088 [TBL] [Abstract][Full Text] [Related]
3. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
4. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272 [TBL] [Abstract][Full Text] [Related]
5. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365 [TBL] [Abstract][Full Text] [Related]
6. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Arafah M Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430 [TBL] [Abstract][Full Text] [Related]
7. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Ridolfi RL; Jamehdor MR; Arber JM Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453 [TBL] [Abstract][Full Text] [Related]
8. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
9. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Hoff ER; Tubbs RR; Myles JL; Procop GW Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143 [TBL] [Abstract][Full Text] [Related]
10. [Her-2 amplification and p185 expression in invasive breast cancer cells in women]. Titi S Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393 [TBL] [Abstract][Full Text] [Related]
11. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622 [TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
14. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Gong Y; Booser DJ; Sneige N Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420 [TBL] [Abstract][Full Text] [Related]
15. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434 [TBL] [Abstract][Full Text] [Related]
16. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926 [TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
19. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker. Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746 [TBL] [Abstract][Full Text] [Related]
20. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]